free counter with statistics
newsverses.com

South Korea probing two deaths after AstraZeneca’s COVID-19 vaccine: KDCA

Get Extra 15% OFF on PureVPN 1-Month Subscription with Coupon Code: 1M15
Get PureVPN

SEOUL: South Korean authorities stated on Wednesday (Mar 3) they’re investigating the deaths of two individuals after a media report stated the pair – each with pre-existing circumstances – died inside days of receiving AstraZeneca’s COVID-19 vaccine.

A 63-year-old nursing residence affected person with cerebrovascular illness developed signs, together with excessive fever, after being given the AstraZeneca vaccine, Yonhap information company reported.

The particular person was moved to a bigger hospital on Tuesday, however died after exhibiting signs of blood poisoning and pneumonia, Yonhap stated.

One other particular person of their 50s with a cardiac dysfunction and diabetes died on Wednesday after struggling a number of coronary heart assaults, having obtained the identical vaccine a day earlier, the company stated.

An official with the Korea Illness Management and Prevention Company (KDCA) instructed Reuters it was investigating the reason for the deaths, however didn’t elaborate or affirm the small print of Yonhap’s report.

An AstraZeneca spokeswoman in Seoul stated the corporate had no remark at current.

READ: No indication that COVID-19 vaccine caused cardiac arrest in elderly Singaporean man: MOH

South Korea started vaccinating its inhabitants final week. By Tuesday midnight, 85,904 individuals had obtained first doses of the AstraZeneca vaccine and 1,524 had been given Pfizer pictures, KDCA stated in a press release.

South Korea reported 444 new confirmed COVID-19 instances on Tuesday, up from 344 on Monday, elevating the nation’s tally to 90,816 infections, with 1,612 deaths.

BOOKMARK THIS: Our complete protection of the coronavirus outbreak and its developments

Obtain our app or subscribe to our Telegram channel for the newest updates on the coronavirus outbreak: https://cna.asia/telegram

Comments are closed.